Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.12383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study.
J Dermatolog Treat
December 2025
Department of Dermatology, Children's Hospital Affiliated to Kunming Medical University, Kunming, China.
To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP). A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: children aged 0-3 years received 75 mg of secukinumab, while those aged 3-12 years received 150 mg.
View Article and Find Full Text PDFA case of treatment-resistant erosive pustular dermatosis of the scalp.
SAGE Open Med Case Rep
January 2025
Memorial University of Newfoundland, St. John's, NL, Canada.
Erosive pustular dermatosis is a rare and chronic inflammatory condition of the scalp which can be mistaken for cutaneous malignancy, precancerous lesions, dermatitis or pyoderma gangrenosum. The recurrent and resistant characteristics of erosive pustular dermatosis of the scalp pose a challenge to successful management and remission of the condition. The purpose of this case report is to provide management options and treatment recommendations for refractory cases of erosive pustular dermatosis of the scalp.
View Article and Find Full Text PDFRecibokibart, an anti-IL-36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial.
J Eur Acad Dermatol Venereol
January 2025
Hospital for Skin Diseases, Shandong First Medical University, Shandong, China.
Rapid improvement in a recurrent generalized pustular psoriasis patient ineffective to Ixekizumab following Spesolimab therapy.
An Bras Dermatol
December 2024
Institute of Dermatology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China. Electronic address:
Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort.
Front Med (Lausanne)
December 2024
Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO Institute, Milan, Italy.
Objectives: The study aims to evaluate the applicability of the D2T psoriatic arthritis (PsA) definition, adapted from rheumatoid arthritis, within a single-center observational cohort of PsA patients treated with b/tsDMARDs. In addition, we aimed to establish a numerical index defining D2T-PsA based on the ratio of observed to expected failed b/tsDMARDs and to develop a predictive model identifying features associated with the D2T condition.
Methods: The study included 267 consecutive adult PsA patients receiving b/tsDMARDs, collecting demographic, clinical, and clinimetric data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!